button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 1.0better0.35.098 %1.0better0.35.0100 %-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 1.0better0.35.0100 %1.0better0.35.0100 %-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 1.0better0.35.096 %1.0better0.35.089 %-

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 1.0better0.35.099 %1.0better0.35.0100 %-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 1.0better0.35.098 %1.0better0.35.0100 %-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 1.0better0.35.096 %1.0better0.35.0100 %-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 1.0better0.35.061 %1.0better0.35.099 %-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.0100 %1.0better0.35.0100 %-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons